Toggle light / dark theme

Can The Pharmaceutical Companies Use Basic Aging Biology To Develop Drugs For Age-Related Diseases?

Posted in finance, life extension

The University of Copenhagen in Denmark is a very unique place. Apart from being one of the oldest universities in Scandinavia, it is also one of the top universities in the world. So far, 39 Nobel laureates have been affiliated with the University and it sports a spectacular center for healthy aging which hosts the Biology of Aging lab. In September 2021 the University of Copenhagen hosted the 8th annual Aging Research and Drug Discovery (ARDD) meeting.

This year’s ARDD meeting, held at the Ceremonial Hall of the University, was the largest conference on aging and biopharma in the world for the second consecutive year.

The conference, which took place from August 31 to September 3, brought together leaders in the field of longevity research with the focus on aging research, drug discovery and biomarker development. Those who regularly read my articles know that I believe that aging research is the emerging trend in the biopharmaceutical industry. The field is well and truly emerging and ARDD is one of the first conferences to credibly bring together pharmaceutical companies, startups, clinicians, venture capital firms, and representatives from academia to the same table.

The first ARDD meeting was held in 2014 at Basil, Switzerland. Back then, the meeting was known as the Aging Forum and was part of the MipTec and Basel Life congresses. From its inception, the conference was intended to bring together the pharmaceutical industry, leading academics, investors, and startups while maintaining a very high level of scientific credibility, while focusing on the translational potential.

Full Story:

Leave a Reply